

[54] METHOD FOR THE PURIFICATION OF LPF-HA

[75] Inventors: Shin Sakuma; Kuniaki Sakamoto; Hisashi Kitagawa; Mitsuo Sakoh; Saneo Nonaka, all of Kumamoto, Japan

[73] Assignee: Juridical Foundation The Chemo-Sero-Therapeutic Research Institute, Kumamoto, Japan

[21] Appl. No.: 666,172

[22] Filed: Oct. 26, 1984

[30] Foreign Application Priority Data

Nov. 1, 1983 [JP] Japan ..... 58-206598

[51] Int. Cl.<sup>4</sup> ..... A61K 39/02; C07K 3/20

[52] U.S. Cl. .... 424/88; 424/92; 435/68; 435/70; 435/822; 530/413

[58] Field of Search ..... 424/88, 92; 435/68; 530/413

[56] References Cited

U.S. PATENT DOCUMENTS

4,247,452 1/1981 Irons et al. .... 260/112 B  
4,551,429 11/1985 Greenspan ..... 424/92  
4,563,303 1/1986 Gennaga et al. .... 424/92

FOREIGN PATENT DOCUMENTS

0035204 9/1981 European Pat. Off. .  
57-2688 1/1982 Japan .

OTHER PUBLICATIONS

*Science*, 127, 1963, p. 588, Morell et al.  
*Infect and Immunity*, 41(1), 1983, pp. 313-320, Sato et al.  
*Infect and Immunity*, 39(2), 1983, pp. 590-598, Robinson et al.  
*C. A.*, vol. 96, 1982, #197728e, Cowell et al.

*Primary Examiner*—John Kight  
*Assistant Examiner*—Garnette D. Draper  
*Attorney, Agent, or Firm*—Wegner & Bretschneider

[57] ABSTRACT

A method for producing highly pure LPF-HA (Leucocytosis-promoting Factor Hemagglutinin) from culture media of *Bordetella pertussis* in a high yield by an affinity chromatography using a denatured ceruloplasmin as a ligand. The LPF-HA obtained by this invention is highly pure and does not contain almost endotoxin of *B. pertussis* and is useful for the preparation of various reagents utilizing the physiological activities, a medicine for treating diabetes, and a pertussis vaccine.

8 Claims, No Drawings